MedPath

AMNEAL PHARMACEUTICALS PRIVATE LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

6

FDA:5
NMPA:1

Drug Approvals

Sevelamer Carbonate Tablets

Product Name
碳酸司维拉姆片
Approval Number
国药准字HJ20230102
Approval Date
Apr 18, 2024
NMPA

Clinical Trials

No trials found

News

Metsera Secures $215 Million to Advance Weight Loss Drug Pipeline

Metsera raised $215 million in a Series B funding round to advance its portfolio of GLP-1 receptor agonists for weight loss, bringing its total funding to over $500 million.

FDA Approves Amneal's Extended-Release Pyridostigmine Bromide Tablets for Nerve Agent Pretreatment

The FDA has approved Amneal's pyridostigmine bromide ER tablets (105 mg) for pretreatment against soman nerve agent poisoning in adults.

FTC Orange Book Patent Challenge Initiative Shows Mixed Results as Most Listings Remain in Force

The Federal Trade Commission has challenged over 400 pharmaceutical patent listings in the FDA's Orange Book since September 2023, claiming many are improperly listed to delay generic competition.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.